In Vitro Activity of Cefditoren against Respiratory Pathogens.
- Author:
Joon Young SONG
1
;
Yu Mi JO
;
Won Suk CHOI
;
Sae Yoon KEE
;
Cheong Won PARK
;
In Sook HWANG
;
Jong Jin HYUN
;
Jang Wook SOHN
;
Chang Gyu LEE
;
Hee Jin CHEONG
;
Woo Joo KIM
;
Min Ja KIM
Author Information
1. Division of Infectious Disease, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. heejinmd@medimail.co.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Cefditoren;
Respiratory tract pathogens;
Antibiotic susceptibility
- MeSH:
Ampicillin Resistance;
Anti-Bacterial Agents;
beta-Lactamases;
Ceftriaxone;
Cephalosporins;
Clarithromycin;
Haemophilus influenzae;
Humans;
Influenza, Human;
Moraxella (Branhamella) catarrhalis;
Outpatients;
Penicillins;
Pneumonia;
Respiratory Tract Infections;
Streptococcus pneumoniae
- From:
Infection and Chemotherapy
2005;37(3):138-143
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Cefditoren is a third generation orally administered cephalosporin with excellent activity against respiratory pathogens. This study was performed to determine the comparative antibacterial activity of cefditoren against clinical isolates of respiratory tract infection. MATERIALS AND METHODS: According to the NCCLS guideline, in vitro activities of cefditoren and other antibiotics were tested against respiratory pathogens including 117 isolates of Streptococcus pneumoniae, 60 isolates of Haemophilus influenzae, and 31 isolates of Moraxella catarrhalis. RESULTS: The level of cefditoren activity against S. pneumoniae (MIC50/90, 0.5/1 microgram/mL) was superior to amoxicillin+/-clavulanate (MIC50/90, 4/16 microgram/mL), clarithromycin (MIC50/90, >32/>32 microgram/mL), and most of the marketed cephalosporins (MIC50/90, 8-64/16-128 microgram/mL). Although the MIC of cefditoren was relatively higher than those of new fluoroquinolone agents (MIC50/90, 0.03-1/0.06-1 microgram/mL), it was comparable to ceftriaxone (MIC50/90, 0.5/1 microgram/mL). In addition, cefditoren was active against two quinolone resistant pneumococci strains with MIC of 0.5 microgram/mL. In detail, cefditoren was active against pneumococci strains with MIC50 and MIC90 values of 0.015/0.12, 0.12/0.5, and 0.5/1 microgram/mL for penicillin-susceptible, -intermediate, and -resistant pneumococci, respectively. Cefditoren was also active against all respiratory isolates of H. influenzae (MIC50/90, 0.03/0.06 microgram/mL) and M. catarrhalis (MIC50/90, 0.03/0.05 microgram/mL) irrespective of beta-lactamase production or ampicillin resistance. CONCLUSION: Cefditoren is considered to be a good option for outpatient treatment of respiratory infections, particulary if there is concern about S. pneumoniae infection with decreased susceptibility to penicillin or beta-lactamase producing organisms.
